511 related articles for article (PubMed ID: 21457235)
1. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.
Tepper SJ; Kori SH; Borland SW; Wang MH; Hu B; Mathew NT; Silberstein SD
Headache; 2012 Jan; 52(1):37-47. PubMed ID: 22106843
[TBL] [Abstract][Full Text] [Related]
4. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
Shrewsbury SB; Kori SH; Miller SD; Pedinoff A; Weinstein S
Curr Med Res Opin; 2008 Jul; 24(7):1977-85. PubMed ID: 18534051
[TBL] [Abstract][Full Text] [Related]
6. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
7. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
8. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
9. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Winner P; Rothner AD; Wooten JD; Webster C; Ames M
Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
[TBL] [Abstract][Full Text] [Related]
10. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
11. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial.
Silberstein SD; Freitag FG; Rozen TD; Kudrow DB; Hewitt DJ; Jordan DM; Fisher AC; Rosenthal NR;
Headache; 2005; 45(10):1317-27. PubMed ID: 16324164
[TBL] [Abstract][Full Text] [Related]
12. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.
Tepper SJ; Kori SH; Goadsby PJ; Winner PK; Wang MH; Silberstein SD; Cutrer FM
Mayo Clin Proc; 2011 Oct; 86(10):948-55. PubMed ID: 21964172
[TBL] [Abstract][Full Text] [Related]
13. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
Hoernecke R; Doenicke A
Med Klin (Munich); 1993 Nov; 88(11):642-8. PubMed ID: 8295604
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
18. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
19. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P; Landy S; Richardson M; Ames M
Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
[TBL] [Abstract][Full Text] [Related]
20. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
